Investor Relations

diaDexus (DDXS.OB), based in South San Francisco, California, develops and commercializes proprietary diagnostic products addressing unmet needs in cardiovascular disease (CVD). diaDexus has two tests cleared by the FDA:

·        The PLAC® Test ELISA Kit is a Lp-PLA2 blood test to aid in predicting risk for both coronary heart disease and ischemic stroke associated with atherosclerosis.

·        The PLAC® Test for Lp-PLA2 Activity is to be used in conjunction with clinical evaluation and patient risk assessment as an aid in predicting risk of coronary heart disease (CHD) in patients with no prior history of cardiovascular events, which represents approximately 75% of coronary heart disease patients.

The Company also has biomarkers for heart failure, with the first marker to enter development by year-end 2014.

Fact Sheet PDF

View all »   RSSRecent Releases

Dec 15, 2014
diaDexus, Inc. Receives FDA Clearance for PLAC Activity Test to Assess Coronary Heart Disease Risk

Dec 10, 2014
diaDexus, Inc. Appoints Pat Arensdorf to Lead Heart Failure Business



 

©2014 diaDexus, Inc. | diaDexus and PLAC are U.S. Registered Trademarks of diaDexus, Inc.